Investing.com -- Coherus BioSciences Inc (NASDAQ:CHRS) stock tumbled 14.5% in premarket trading on Friday after the oncology company announced the pricing of a public offering of 28.6 million shares ...
Coherus Oncology (CHRS) has priced an underwritten public offering of 28.6M shares at $1.75 per share. The company expects to ...
Detailed price information for Coherus Oncology Inc (CHRS-Q) from The Globe and Mail including charting and trades.
COHERUS BIOSCIENCES ($CHRS) posted quarterly earnings results on Monday, March 10th. The company reported earnings of -$0.28 per share, missing estimates of -$0.13 by ...
COHERUS BIOSCIENCES ($CHRS) is expected to release its quarterly earnings data on Monday, May 12th after market close, per Finnhub. Analysts are expecting revenue of ...
Coherus Oncology remains a speculative play, with a strong cash position post-Udenyca sale and a cash runway into 2026 supporting ongoing pipeline development. Toripalimab sales are steady but limited ...
Detailed price information for Coherus Oncology Inc (CHRS-Q) from The Globe and Mail including charting and trades.
Hello everyone and welcome to the Coherus Fourth Quarter Year Ending 2024 Financial Results Conference call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, ...
Coherus BioSciences (NASDAQ:CHRS) is gearing up to announce its quarterly earnings on Thursday, 2025-11-06. Here's a quick overview of what investors should know before the release. Analysts are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results